- Mike Peters in remission from lymphoma
- Experimental NHS drug trial successful
- Stem cell transplant upcoming
Mike Peters, the lead singer of rock band The Alarm, has announced he is in remission from an aggressive form of cancer, thanks to participation in an NHS drug trial.
The 65-year-old musician, who hails from Dyserth, North Wales, was diagnosed with Richter’s Syndro a fast-growing lymphoma in April, forcing him to cancel a planned US tour. However, following experimental therapy at The Christie NHS Foundation Trust in Manchester, he has now received the all-clear.
“Having complete remission thanks to this trial has been incredible,” Peters said, expressing his relief and gratitude.
Currently, medical professionals are working to find a suitable donor for Peters to undergo a stem cell transplant, which is necessary to prevent the leukemia from recurring. The singer has a long history with cancer, having first been diagnosed with chronic lymphocytic leukemia (CLL) over 29 years ago at the age of 36.
Just five days before he was set to fly to Chicago for a 50-date US tour in April, Peters discovered a lump in his neck. He was subsequently referred from the North Wales Cancer Centre to The Christie, where he participated in a drug trial that involved a targeted therapy called acalabrutinib alongside standard chemotherapy. Although acalabrutinib is already approved for CLL, its effectiveness in combination with chemotherapy for Richter’s Syndrome had not been previously tested.
“It’s amazing; I feel fortunate to be in remission,” Peters remarked. He added, “I now need to find the right match for the stem cell transplant and, if it’s successful, and with the incredible help of the team at the Christie, endeavour to find a way to be cured once and for all.”
Peters also acknowledged the “phenomenal support and prayers” he has received from thousands of fans during his battle with cancer.
Professor Adrian Bloor, a consultant haematologist at The Christie, commented on the significance of Peters’ case, stating, “It is hoped that the combination of acalabrutinib with chemotherapy will be effective in treating Richter’s syndrome and stopping it coming back.”
